Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT

NCT02728895 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Allogeneic Hematopoietic Stem Cell Transplantation

Interventions

DRUG: Vedolizumab

Sponsor

Takeda